Evidence for the rapid conversion of stephacidin B into the electrophilic monomer avrainvillamide in cell culture

Journal of the American Chemical Society

Volumn 129, Issue 16, 2007, Pages 4898-4899

  Wulff, Jeremy E ^a   Herzon, Seth B ^a   Siegrist, Romain ^a   Myers, Andrew G ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID DERIVATIVE; AVRAINVILLAMIDE; MONOMER; STEPHACIDIN B; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CELL CULTURE; CELL DIVISION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; NONHUMAN; PROTEIN BINDING; WESTERN BLOTTING;

CELL PROLIFERATION; CYSTEINE; HUMANS; INDOLE ALKALOIDS; INDOLES; NEOPLASM PROTEINS; NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 34247540356     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja0690971     Document Type: Article

References (22)

1. (a) Qian-Cutrone, J.; Krampitz, K. D.; Shu, Y.-Z.; Chang, L.-P.; Lowe, S. E. Stephacidin Antitumor Antibiotics. U.S. Patent 6,291,461, 2001.
2. (b) Qian-Cutrone, J.; Huang, S.; Shu, Y.-Z.; Vyas, D.; Fairchild, C.; Menendez, A.; Krampitz, K.; Dalterio, R.; Klohr, S. E.; Gao, Q. J. Am. Chem. Soc. 2002, 124, 14556-14557.
3. (a) Fenical, W.; Jensen, P. R.; Cheng, X. C. Avrainvillamide, a Cytotoxic Marine Natural Product, and Derivatives Thereof. U.S. Patent 6,066,635, 2000. (+)-Avrainvillamide (2) was independently isolated under the name CJ-17,665:
4. (b) Sugie, Y.; Hirai, H.; Inagaki, T.; Ishiguro, M.; Kim, Y.-S.; Kojima, Y.; Sakakibara, T.; Sakemi, S.; Sugiura, A.; Suzuki, Y.; Brennan, L.; Duignan, J.; Huang, L. H.; Sutcliffe, J.; Kojima, N. J. Antibiot. 2001, 54, 911-916.
5. von Nussbaum, F. Angew. Chem., Int. Ed. 2003, 42, 3068-3071.
6. Herzon, S. B.; Myers, A. G. J. Am. Chem. Soc. 2005, 127, 5342-5344.
7. (a) Baran, P. S.; Guerrero, C. A.; Hafensteiner, B. D.; Ambhaikar, N. B. Angew. Chem. Int. Ed. 2005, 44, 3892-3895.
8. (b) Baran, P. S.; Hafensteiner, B. D.; Ambhaikar, N. B.; Guerrero, C. A.; Gallagher, J. D. J. Am. Chem. Soc. 2006, 128, 8678-8693.
9. Roswell Park Memorial Institute culture medium, series 1640, was purchased from ATCC. For formulation, see: Moore, G. E.; Gerner, R. E.; Franklin, H. A. J. Am. Med. Assoc. 1967, 199, 519-524.
10. This experiment employed the unnatural enantiomers ((+)-1 and (-)-2), which we had synthesized first.
11. Myers, A. G.; Herzon, S. B. J. Am. Chem. Soc. 2003, 125, 12080-12081.
12. 50 for (+)-2 was 330 nM vs. LNCaP and 420 nM vs. T-47D.
13. Bogyo, M.; Baruch, A.; Jeffery, D. A.; Greenbaum, D.; Borodovsky, A.; Ovaa, H.; Kessler, B. Curr. Protoc. Protein Sci. 2004, 21, 17.1.
14. (a) Liu, Y.; Patricelli, M. P.; Cravatt, B. F. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 14694-14699.
15. (b) Kidd, D.; Liu, Y.; Cravatt, B. F. Biochemistry 2001, 40, 4005-4015.
16. (a) Karplus, P. A.; Schulz, G. E. J. Mol. Biol. 1987, 195, 701-729.
17. (b) Becker, K.; Savvides, S. N.; Keese, M.; Schirmer, R. H.; Karplus, P. A. Nat. Struct. Biol. 1998, 5, 267-271.
18. Wood, Z. A.; Schröder, E.; Harris, J. R.; Poole, L. B. Trends Biochem. Sci. 2003, 28, 32-40.
19. (a) Nagumo, Y.; Kakeva, H.; Shoji, M.; Hayashi, Y.; Dohmae, N.; Osada, H. Biochem. J. 2005, 387, 835-840.
20. (b) Nagumo, Y.; Kakeya, H.; Yamaguchi, J.; Uno, T.; Shoji, M.; Hayashi, Y.; Osada, H. Bioorg. Med. Chem. Lett. 2004, 14, 4425-4429.
21. Kudo, N.; Matsumori, N.; Taoka, H.; Fujiwara, D.; Schreiner, E. P.; Wolff, B.; Yoshida, M.; Horinouchi, S. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 9112-9117.
22. Control experiments (lanes 6-8 of Figure 2) with compounds lacking either the biotin moiety (2 or 3) or the 3-alkylidene-3H-indole 1-oxide function (6) did not afford detectable quantities of protein in subsequent Western-blot analyses.